(Q37132598)

English

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

scientific article published on April 2008

Statements

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In (English)
Frances A Shepherd
Thomas A Puchalski

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit